Novanta's Transformative Riverpoint Deal and Organic Growth Acceleration
Medical pivot and AI tailwinds drive raised outlook.
NOVT · Earnings Call · 2026-08-06
Riverpoint Medical: A Transformative Acquisition
The quarter's headline was the close of Riverpoint Medical, Novanta's largest acquisition to date, which reshapes the portfolio toward higher-growth medical consumables. CEO Matthijs Glastra opened the call with a clear sense of momentum: “Novanta delivered an outstanding second quarter.” — Matthijs Glastra, Chair and Chief Executive Officer · 2026-08-06 The deal doubles the company's recurring medical consumable revenue to roughly $300 million, expanding medical end-market exposure to 60% of revenue. Riverpoint Medical is a strategic step that management expects to be immediately accretive to growth, margins, and EPS.Organic Growth Accelerates Across AI and Medical
Underlying the M&A, organic growth accelerated to 9% in Q2, driven by a Automation Enabling Technologies segment that grew 12% year-over-year. The robotics and automation business, a key beneficiary of the physical AI theme, expanded 13.5%, with first significant orders for servo drives into humanoid training fleets. Chuck Ravetto noted: “We have seen our first significant orders of our servo drives to support the deployment of hundreds of humanoids in customers' testing and learning facilities...” — Charles Ravetto, Automation Enabling Technologies Segment Leader or Executive · 2026-08-06 Management also quantified its AI infrastructure exposure at roughly 17% of revenue, up from 15% in Q1, with applications such as GPU drilling and advanced packaging contributing to growth. This AI-driven demand, particularly in data centers and advanced packaging, aligns with a broader semiconductor upcycle, but Novanta's niche leadership in components like air bearing spindles and laser beam steering gives it a defensible position. This momentum reflects themes management has been cultivating for over a year. In February, Matthijs told analysts: “Yeah. I mean, we see that momentum building very steadily.” — Matthijs Glastra, Chair and Chief Executive Officer · 2026-02-24 And in May, he emphasized the company's unique position: “...we have unique competencies and capabilities where we're often the only ones in the world...” — Matthijs Glastra, Chair and Chief Executive Officer · 2026-05-12Margin Expansion and a Raised Outlook
On the operational side, Novanta accelerated its manufacturing rationalization by announcing two additional factory closures, while still guiding to higher gross margins. CFO Robert Buckley highlighted the balance: “Despite all the headwinds that we're seeing, even the inflationary pressures, we're still expanding gross margins 100 basis points this year and 100 basis points next year.” — Robert Buckley, Chief Financial Officer · 2026-08-06 The non-GAAP gross margin reached 47% in Q2, up 100 basis points year-over-year, with Q3 guided to approximately 48%. The company's gross margin has expanded from 44% a decade ago to 47% today, with management confident in further gains as site rationalization and the Riverpoint mix take hold. Financially, the quarter was strong: adjusted EBITDA grew 16% to $60.7M, adjusted EPS rose 17% to $0.89, and operating cash flow nearly quadrupled year-over-year to $65M. Year-to-date cash flow exceeded all of 2025, providing ample capital for further M&A or buybacks. The company finished Q2 with net cash of ~$480M, enabling the Riverpoint acquisition without stretching leverage. The full-year outlook was raised to revenue of $1.13-1.14 billion, representing reported growth of more than 15%, with adjusted EBITDA expected between $273-278 million, up 24-26%. Robert's summary captured the confidence:The market has responded positively, with the stock up 16% over the last 90 days, though still below its 2024 peak. However, the real story is the durability of the organic growth engine and the strategic pivot towards medical consumables, which should provide a more stable and higher-margin revenue base going forward.We just delivered our strongest organic growth and cash flow growth in the last 3 years.